T

The Acurio Health Group | Sydney Retina Clinic and Day Surgery

Research site
(Unclaimed)
Location
Level 13/187 Macquarie Street, Sydney, New South Wales, Australia

Site insights

Top conditions

Top treatments

Ranibizumab
Faricimab
APL-2
Zimura
Triamcinolone Acetonide
RG7774
IONIS-FB-LRx
Pegcetacoplan
JNJ-81201887
Abicipar Pegol

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 18 total trials

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Device: Port Delivery System with Ranibizumab
Drug: Ranibizumab

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Enrolling
Choroidal Neovascularization Secondary to Pathologic Myopia
Procedure: Sham Procedure
Drug: Faricimab

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)...

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Placebo
Drug: IONIS-FB-LRx

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Enrolling
Age-Related Macular Degeneration
Biological: VOY-101

Trial sponsors

Roche logo
Allergan logo
A
B
C
Genentech logo
Ionis Pharmaceuticals logo
I
Janssen (J&J Innovative Medicine) logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems